BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22968380)

  • 1. Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis.
    Welle MK
    Orthop Nurs; 2012; 31(5):265-78; quiz 279-80. PubMed ID: 22968380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
    Ageno W; Spyropoulos AC; Turpie AG
    Thromb Haemost; 2012 Jun; 107(6):1027-34. PubMed ID: 22437976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological thromboprophylaxis and total hip or knee replacement.
    Frostick S
    Br J Nurs; 2016 Jan 14-27; 25(1):45-53. PubMed ID: 26768045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
    Merli G; Spyropoulos AC; Caprini JA
    Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
    Dager WE
    Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants for thromboprophylaxis after total knee arthroplasty.
    Brown TS; Huo MH
    Am J Orthop (Belle Mead NJ); 2013 Sep; 42(9):424-9. PubMed ID: 24078968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants.
    Wharin C; Tagalakis V
    Blood Rev; 2014 Jan; 28(1):1-8. PubMed ID: 24360911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of new anticoagulants in primary practice.
    Perez A; Eraso LH; Merli GJ
    Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unanswered questions in venous thromboembolism.
    Weitz JI
    Thromb Res; 2009; 123 Suppl 4():S2-S10. PubMed ID: 19303498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving prevention and treatment of venous thromboembolism: clinical trial results.
    Mahan C; Spyropoulos AC
    J Med Econ; 2012; 15(4):611-22. PubMed ID: 22372589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention and treatment of venous thromboembolism: the place of new oral anticoagulants].
    Reis A
    Rev Port Cardiol; 2012 Apr; 31 Suppl 1():45-50. PubMed ID: 22541035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options for anticoagulation following total hip arthroplasty and total knee arthroplasty: new oral agents on the horizon.
    Amin A
    Hosp Pract (1995); 2012 Aug; 40(3):19-26. PubMed ID: 23086091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.